A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology

Area of Science:

• Vaccinology
• Immunology
• Biotechnology

Background:

• Existing SARS-CoV-2 vaccines necessitate complementary options for global accessibility.
• A novel immune-activating platform technology has been developed to address this need.

Purpose of the Study:

• To report initial findings on a SARS-CoV-2 vaccine candidate (OMN008) utilizing a novel recombinant protein platform.
• To assess the safety, efficacy, and production scalability of the OMN008 vaccine.

Main Methods:

• The OMN008 vaccine platform utilizes recombinant protein production in insect cells via baculoviral expression.
• Vaccine efficacy was evaluated based on antigenicity, neutralization, and T-cell responses.

Main Results:

• Unadjuvanted OMN008 vaccination demonstrated robust antigenicity and neutralization capabilities.
• OMN008 vaccination successfully induced a specific CD8 T-cell response.
• The production infrastructure is amenable to rapid scale-up, suggesting potential for low-cost manufacturing.

Conclusions:

• OMN008 presents a promising candidate vaccine for SARS-CoV-2, potentially filling gaps in current global vaccine availability.
• Further optimization is required, but the platform's inherent characteristics suggest cost-effective production.